%{search_type} search results

340 catalog results

RSS feed for this result
Book
xxvi, 406 p. : ill. (some col.)
  • Preface XIX List of Contributors XXIII 1 Introduction to Sample Management 1 William P. Janzen and Andy Zaayenga References 6 2 Generating a High-Quality Compound Collection 9 Philip B. Cox and Anil Vasudevan 2.1 Defining Current Screening Collections 9 2.2 Design Criteria for Enriching a Compound Collection with Drug-Like Compounds 10 2.3 Concluding Remarks 20 References 20 3 Assessing Compound Quality 23 Ioana Popa-Burke, Stephen Besley, and Zoe Blaxill 3.1 Introduction 23 3.2 Process Quality and Analytical Quality in Compound Management 24 3.3 Identity 28 3.4 Purity/Stability 32 3.5 Concentration/Solubility 39 3.6 Conclusions 41 Acknowledgments 41 References 42 Further Reading 44 4 Delivering and Maintaining Quality within Compound Management 45 Isabel Charles 4.1 Introduction 45 4.2 What is Quality from a Compound Management Perspective? 46 4.3 Storage and Delivery of Samples in Solution 47 4.4 Intercepting Low Purity 49 4.5 Storage and Delivery of Solids 51 4.6 Automation Quality Control and Reliability 52 4.7 High-Quality Data Management 54 4.8 Conclusion 55 Acknowledgments 56 References 56 5 Obtaining and Maintaining High-Quality Tissue Samples: Scientific and Technical Considerations to Promote Evidence-Based Biobanking Practice (EBBP) 59 Lisa B. Miranda 5.1 Introduction 59 5.2 The Path toward Integration of Evidence-based Biobanking Practice 62 5.3 Integrating Evidence-based Biobanking Practice into Sample Protocols 66 5.4 Final Thoughts and Recommendations 74 References 79 6 Thinking Lean in Compound Management Laboratories 83 Michael Allen 6.1 The Emergence of 'Lean Thinking' 83 6.2 The Application of 'Lean Thinking' 83 6.3 Lean Thinking in Drug Discovery 86 6.4 A Lean Laboratory Toolbox 87 6.5 Streamlining Compound Processing -An Example 101 6.6 Summary 103 References 105 7 Application of Supply Management Principles in Sample Management 107 Paul A. Gosnell 7.1 Introduction 107 7.2 Common Pitfalls of Sample Management 107 7.2.1 One Size Does Not Fit All 108 7.3 Sample Management and Supply Chain Concepts 108 7.4 Implementing the Sample Management Strategy 111 7.5 Sample Management Organization 111 7.6 Sample Management Informatics 113 7.7 Avoid Monolithic Silos of Excellence 114 7.8 Position and Synchronize Inventory 115 7.9 Expand the Sample Management Boundary 117 7.10 Measuring and Assessing Effectiveness and Quality 118 7.11 Conclusions 119 References 120 8 Solid Sample Weighing and Distribution 121 Michael Gray and Snehal Bhatt 8.1 The Practicalities and Technology of Weighing Solid Compounds 121 8.2 Logistical Challenges of Transportation of Small Molecules 127 References 142 9 Managing a Global Biological Resource of Cells and Cellular Derivatives 143 Frank P. Simione and Raymond H. Cypess 9.1 Introduction 143 9.2 Diversity of Collections 144 9.3 Sourcing and Acquisition 148 9.4 Authentication and Characterization 149 9.5 Cryopreservation, Storage, and Production 153 9.6 Data Management 154 9.7 Quality and Standards 155 9.8 Order Fulfillment and Distribution 157 9.9 Offsite Biorepository Management 158 9.10 Regulatory and Legal Compliance 159 9.11 Ownership and Intellectual Property Management 160 9.12 Collaborations 161 9.13 Conclusion 162 References 163 10 Development of Automation in Sample Management 165 Gregory J. Wendel 10.1 Introduction 165 10.2 Historical Background 165 10.3 Automation of Sample Management Today 167 10.4 System Building Blocks 169 10.5 Storage Systems 171 10.6 Liquid Handler 175 10.7 Accessories 180 10.8 Plate Handling, Integration 184 10.9 Case Study: Evolution of a Compound Management Group 186 10.10 Results 196 References 197 11 Applications of Acoustic Technology 199 Eric Tang, Colin Bath, and Sue Holland-Crimmin 11.1 Introduction 199 11.2 Compound-Handling Challenges in Drug Discovery 201 11.3 Acoustic Drop Ejection -Performance, Quality Assurance, and Platform Validation 203 11.4 Acoustic-Assisted Compound Solubilization and Mixing 206 11.5 Acoustic Applications in Drug Discovery 209 11.6 Emerging Applications 216 References 218 12 Enhancing Biorepository Sample Integrity with Automated Storage and Retrieval 221 Johann van Niekerk 12.1 The Emerging Growth of Biobanking 221 12.2 Automated Storage and Retrieval in a Biorepository 225 12.3 Configuration of an Automated Biorepository 236 12.4 Conclusions 241 References 241 13 Information Technology Systems for Sample Management 243 Brian Brooks 13.1 Sample Registration 243 13.2 Intellectual Property and Laboratory Notebooks 253 13.3 Some Observations on Information Technology 254 13.4 Biological Data Management 255 Dedication and Acknowledgments 263 14 Key Features of a Compound Management System 265 Clive Battle 14.1 Why Do We Need Compound Management Information Technology Systems? 265 14.2 Compound Management Software 266 14.3 Benefits of Commercially Available Compound Management Systems 272 References 273 15 What Does an HTS File of the Future Look Like? 275 Francois Bertelli 15.1 Introduction 275 15.2 History of Compounds Collection for HTS 276 15.3 Impact of High-Throughput Chemistry on Corporate Files 277 15.4 Chemical Library Management 278 15.5 The Concept of Drug-Likeness and the Lipinski Rules 279 15.6 Quality versus Quantity 283 15.7 The Emergence of the Subsets: Fragment, G-Protein-Coupled Receptor (GPCR), Ion Channel, Kinase, Protein-Protein Interaction, Chemogenomics, Library Of Pharmacologically Active Compounds (LOPAC), Central Nervous System (CNS), and Diversity 285 15.8 Re-designing the Corporate File for the Future 291 15.9 Future Routes for Hit Identification 299 References 301 16 New Enabling Technology 305 Neil Hardy, Ji Yi Khoo, Shoufeng Yang, Holger Eickhoff, Joe Olechno, and Richard Ellson 16.1 Introduction 305 16.2 A Drop-On-Demand Printer for Dry Powder Dispensing 307 16.3 Piezo Dispense Pens: Integrated Storage and Dispensing Devices and their Potential in Secondary Screening and Diagnostic Manufacturing 312 16.4 Future Directions in Acoustic Droplet Ejection Technology 323 16.5 Closing Remarks 347 References 347 17 The Impact of Future Technologies within Biobanking 351 Manuel M. Morente, Laura Cereceda, and Mar'ia J. Artiga 17.1 Introduction 351 17.2 The Role of Biobanks in Biomedical Research 351 17.3 The Increasing Complexity of Biobanking 354 17.4 Future Technologies and Biobanking: How Could New Technologies Affect the Daily Activities of Biobanks? 356 17.5 The Future of Biobanking Does Not Depend on Technological Developments Alone 363 17.6 Conclusions 364 Acknowledgments 364 References 364 18 Outsourcing Sample Management 367 Sylviane Boucharens and Amelia Wall Warner 18.1 Outsourcing in the Pharmaceutical Industry 367 18.2 Outsourcing Biological Specimen Collections 374 18.3 Conclusions 378 Acknowledgments 378 References 378 19 Sample Management Yesterday and Tomorrow 381 Terry Wood and Mark Wigglesworth 19.1 The Role of Sample Management 381 19.2 Automation of Compound Management 382 19.3 Compound Integrity 384 19.4 Reduction of Redundancy 386 19.5 The Future of Sample Management? 387 19.6 Concluding Remarks 390 References 391 Index 393.
  • (source: Nielsen Book Data)9783527328222 20160610
Filling an obvious gap in the scientific literature, this practice-oriented reference is the first to tie together the working knowledge of large screening centers in the pharmaceutical and biotechnological field. It spans the entire field of this emerging discipline, from compound acquisition to collection optimization for specific purposes, to technology and quality control. In so doing, it applies two decades of expertise gathered by several large pharmaceutical companies to current and future challenges in high-throughput screening. With its treatment of libraries of small molecules as well as biobanks containing biomolecules, microorganisms and tissue samples, this reference is universally applicable for any molecular scientist involved in a large screening program.
(source: Nielsen Book Data)9783527328222 20160610
Book
4 v. (cxxxviii, 1886 p.) : ill. (some col.) ; 24 cm. + 1 CD-ROM (4 3/4 in.)
Due to the impressive accumulation of out-standing results, presented by brilliant, privileged and creative thinkers, this unique book reads like the 'Who is Who' of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max-Planck-Institute, Fraunhofer-Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG. Published as a comprehensive four volume set, this title also includes a CD-ROM containing additional information and videos."Modern Biopharmaceuticals" describes: The first cloned human embryo; the first myocardial regeneration with embryonic stem cells; the first artificial kidney; the first biopharmaceutical from a transgenic animal; the first individualized medicine; the first plasma-free Factor VIII; the first approved human cell line; and, the first oral insulin, etc. '...an outstanding collection of articles from groundbreaking scientists, comprehensively describing the many novel ways cells are being deployed toward human good . ..' - James D. Watson, 'DNA Codebreaker' & Nobel Prize Laureate (Physiology or Medicine, 1962). "Modern Biopharmaceuticals" is an essential reference work for biotechnologists, clinicians, medical doctors, pharmacists, pharmaceutical chemists, bio-chemists, molecular biologists, medicinal chemists, as well as all those working in the biotechnological and pharmaceutical industries, or medicinal institutes.
(source: Nielsen Book Data)9783527311842 20160528
Book
1 online resource (xxv, 451 pages) : illustrations
Journal/Periodical
v. : ill. (some col.) ; 28 cm.
Journal/Periodical
volumes
Book
1 online resource.
  • 1. Introduction of Mid-Size Drugs and Peptidomimetics.- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics.- 3. Conformational-restricted Cyclic Peptides.- 4. Peptidomimetics that Mimic Secondary Structures of Peptides.- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides.- 6. Conjugated Compounds Involving Peptides.- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs.
  • (source: Nielsen Book Data)9789811076909 20180430
This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry.
(source: Nielsen Book Data)9789811076909 20180430
Book
1 online resource (465 pages) : illustrations
Book
1 online resource (xxviii, 203 pages) : illustrations (some color)
Book
1 online resource (505 pages) : illustrations (some color)
Book
1 online resource (505 pages) : illustrations (some color)
Book
ix, 594 p. : ill. (some col.) ; 24 cm.
  • Nanopharmaceutics and Clinical Therapy : Nanomaterials for Drug Delivery-- Nanomaterials for Gene Therapy-- Nanomaterials for Chemotherapy-- Nanomaterials for Pharmaceutics: Polymeric Nanomaterials-- Inorganic Nanomaterials-- Organic Nanomaterials-- Carbon Nanomaterials-- Multifunctional Nanomaterials-- Application in Pharmaceutical Development: Drug Screening-- Therapeutic Pharmaceutics-- Diagnostic Pharmaceutics and Detection.
  • (source: Nielsen Book Data)9789814368667 20160610
Nanomaterials, with their unique size-dependent physical and chemical properties, have shown promising advantages as drug and gene delivery vehicles, ultra-sensitive intracellular detectors and novel therapeutic drugs. Nanopharmaceutics is one of the disciplines that will benefit the most from this technology. Nanotechnology will have a revolutionary impact on cancer diagnosis and therapy due to the exceptional characteristics of nanopharmaceutics. This book provides an overview of some tools, methods, and materials of nanotechnology that offer potential applications in pharmaceutics, followed by a series of examples showing applications that are already in development. It may very well inspire researchers to develop a new generation of pharmaceutics with inventive non-traditional approach and employ nanoscale science for the benefit of the patient.
(source: Nielsen Book Data)9789814368667 20160610
Science Library (Li and Ma)
Book
1 online resource (225 pages)
The pharmaceutical industry needs a shot in the arm - and not a moment too soon. The executive suite is mired in a bygone era, a time when extensive, well-funded pharmaceutical R&D produced blockbuster drugs, kept everything in-house and reaped the financial rewards. But that way of working needs to change. Executives now need to know what the technologists in their companies are doing in order to survive the next decade. Written for those new to industry, as well as for experienced professionals or specialists looking to expand their knowledge, this book is a must-read for business executives and information technologists alike. Pharma's Prescription bridges the knowledge gap between current business practices and the most valuable technologies today. This book is filled with practical, real-life examples from industry and is a straightforward guide for all pharmaceutical and information technology executives who need to improve their businesses. It focuses on practical solutions that are easily incorporated in your day-to-day work. It integrates business operations and information technology. It highlights the industry's top turn-around stories. It discusses pharmaceutical industry trends, growth opportunities, innovation drivers, regulatory complexities, and emerging market operations.
(source: Nielsen Book Data)9780124076624 20160612
Book
xiv, 321 p.
dx.doi.org SpringerLink
Book
1 online resource (3 v.) : ill.
  • Volume 2: Asceptic Manufacturing Facility Design Mark Caldwell, Bob Helt, Beth Holden, Francesca McBride, and Kevin Schreier Personnel and their impact on Cleanroom Operations Jeanne Moldenhauer The Fundamentals of an Environmental Control Program William H. Miele Water Systems for Parenteral Facilities J. Manfredi Particulate Matter: Sub-Visible D. Scott Aldrich Endotoxin Testing Michael E. Dawson The Compendial Sterility Tests Scott VW Sutton Industrial Sterilization Technologies: Principles and Overview Anne F. Booth Steam Sterilization James Agalloco Gas, Vapor and Liquid Chemical Sterilization James Agalloco Dry Heat Depyrogenation and Sterilization Deborah Havlik and Kevin Trupp Radiation Sterilization Barry P. Fairand and Dusan Razem Filters and Filtration Maik W. Jornitz and Theodore H. Meltzer Processing of Small Volume Parenterals (SVPs) and Large Volume Parenterals (LVPs) Donald A. Eisenhauer, Christine Martin, Roland Schmidt, and Steven G. Schultz Freeze Drying: Principles and Practice Steven L. Nail and Larry A. Gatlin.
  • (source: Nielsen Book Data)9781420086454 20160612
  • Volume 3: CGMP Regulations of Parenteral Drugs Terry E. Munson Risk Assessment and Mitigation in Aseptic Processing James Agalloco and James Akers Validation of Drug Product Manufacturing Processes: NCEs and NBEs Karoline Bechtold-Peters Visual Inspection Maria Toler and Sandeep Nema Advances in Parenteral Injection Devices and Aids Donna L. French and James J. Collins, Jr. SiRNA Targeting Using Injectable Nano-based Delivery Systems Lan Feng and Russell J. Mumper Excipients for Parenteral Dosage Forms: Regulatory Considerations and Controls Sandeep Nema Techniques to Evaluate Damage and Pain on Injection Gayle A. Brazeau, Jessica Klapa and Pramod Gupta Parenteral Product Specifications and Stability Michael Bergren Extractables and Leachables Edward Smith and Dianne M. Paskiet Process Analytical Technology and Rapid Microbial Methods Geert Verdonk and Tony Cundell Quality Assurance Michael Gorman Application of Quality by Design in CMC Development Roger Nosal, Tom Garcia, Vince McCurdy, Amit Banerjee, Carol F. Kirchhoff, Satish K. Singh Future of Parenteral Manufacturing James Agalloco, James Akers, and Russell Madsen.
  • (source: Nielsen Book Data)9781420086478 20160612
  • Volume I Parenteral Dosage Forms: Introduction and Historical Perspectives John D. Ludwig Parenteral Drug Administration: Routes of Administration and Devices Himanshu Bhattacharjee and Laura A. Thoma Biopharmaceutics and Immunogenicity of Biotherapeutics Balaji Agoram, Kazuko Sagawa, Ravi M Shanker, and Satish Singh Preformulation Research of Parenteral Medication Murti Vemuri Formulation Development of Small and Large Volume Injections Madhav Kamat and Patrick P. DeLuca Solubility and Solubilization Michael Hageman Formulation of Depot Delivery Systems James J. Cunningham, Marc J. Kirchmeier, and Sachin Mittal Biophysical and Biochemical Characterization of Peptide and Protein Drug Product Tapan K. Das and James A. Carroll Formulation of Protein- and Peptide-based Parenteral Products Gaozhong Zhu and Y. John Wang Development of Ophthalmic Formulations Paramita Bandyopadhyay, Martin J. Coffey, and Mohannad Shawer Glass containers for Parenteral Products Robert Swift Plastic Packaging for Parenteral Drug Delivery Vinod D. Vilivalam and Fran DeGrazio Elastomeric Closures for Parenterals Renaud Janssen Parenteral Product Container-Closure Integrity Testing Dana Morton Guazzo.
  • (source: Nielsen Book Data)9781420086430 20160612
This three-volume set of Pharmaceutical Dosage Forms: Parenteral Medications is an authoritative, comprehensive reference work on the formulation and manufacture of parenteral dosage forms, effectively balancing theoretical considerations with the practical aspects of their development. As such, it is recommended for scientists and engineers in the pharmaceutical industry and academia, and will also serve as an excellent reference and training tool for regulatory scientists and quality assurance professionals. First published in 1984 (as two volumes) and then last revised in 1993 (when it grew to three volumes), this latest revision will address the plethora of changes in the science and considerable advances in the technology associated with these products and routes of administration. The third edition of this book maintains the features that made the last edition so popular but comprises several brand new chapters, revisions to all other chapters, as well as high quality illustrations. Volume one presents: A historical perspective of injectable drug therapy, common routes of administration, and biopharmaceutics of NCEs and NBEs. An in-depth discussion on the preformulation and formulation of small and large molecules, including ophthalmic dosage forms. A presentation of parenteral primary packaging options - glass and plastic containers, as well as elastomeric closures. A definitive chapter on container-closure integrity. New chapters on solubility and solubilization, formulation of depot delivery systems and biophysical/biochemical characterization of proteins.
(source: Nielsen Book Data)9781420086430 20160612
This three-volume set of Pharmaceutical Dosage Forms: Parenteral Medications is an authoritative, comprehensive reference work on the formulation and manufacture of parenteral dosage forms, effectively balancing theoretical considerations with the practical aspects of their development. As such, it is recommended for scientists and engineers in the pharmaceutical industry and academia, and will also serve as an excellent reference and training tool for regulatory scientists and quality assurance professionals. First published in 1984 (as two volumes) and then last revised in 1993 (when it grew to three volumes), this latest revision will address the plethora of changes in the science and considerable advances in the technology associated with these products and routes of administration. The third edition of this book maintains the features that made the last edition so popular but comprises several brand new chapters, revisions to all other chapters, as well as high quality illustrations. Volume three presents: * An in-depth discussion of regulatory requirements, quality assurance, risk assessment and mitigation, and extractables/leachables. * Specific chapters on parenteral administrations devices, injection site pain assessment, and parenteral product specifications and stability testing. * Forward-thinking discussions on the future of parenteral product manufacturing, and siRNA delivery systems. * New chapters covering recent developments in the areas of visual inspection, quality by design (QbD), process analytical technology (PAT) and rapid microbiological methods (RMM ), and validation of drug product manufacturing process.
(source: Nielsen Book Data)9781420086478 20160612
This three-volume set of Pharmaceutical Dosage Forms: Parenteral Medications is an authoritative, comprehensive reference work on the formulation and manufacture of parenteral dosage forms, effectively balancing theoretical considerations with the practical aspects of their development. As such, it is recommended for scientists and engineers in the pharmaceutical industry and academia, and will also serve as an excellent reference and training tool for regulatory scientists and quality assurance professionals. First published in 1984 (as two volumes) and then last revised in 1993 (when it grew to three volumes), this latest revision will address the plethora of changes in the science and considerable advances in the technology associated with these products and routes of administration. The third edition of this book maintains the features that made the last edition so popular but comprises several brand new chapters, revisions to all other chapters, as well as high quality illustrations. Volume two presents: * Chapters on aseptic facility design, environmental monitoring, and cleanroom operations. * A comprehensive chapter on pharmaceutical water systems. * A discussion of quality attributes of sterile dosage forms, including particulate matter, endotoxin, and sterility testing. * A detailed chapter on processing of parenteral drug products (SVPs and LVPs). * Presentations on widely used sterilization technologies - steam, gas / chemical, radiation, filtration and dry heat. * An in-depth chapter on lyophilization.
(source: Nielsen Book Data)9781420086454 20160612
Book
xiv, 222 p. : ill.
  • Introduction Fundamentals Fluid Flow Heat Transfer Mass Transfer Powders Processes Air Conditioning and Humidification Drying Solid-Liquid Extraction Crystallization Evaporation and Distillation Filtration Size, Reduction and Classification Mixing Solid Dosage Forms Sterilization Bioprocessing Quality Principles Quality by Design Statistical Experimental Design Process Analytical Technology Conclusion.
  • (source: Nielsen Book Data)9781420084764 20160612
With step-by-step methods of drug production and knowledge of major unit operations and key concepts of pharmaceutical engineering, this guide will help to improve communication among the varied professionals working in the pharmaceutical industry. Key features: REVISION OF A BESTSELLER - Updates include recent advances in the field to keep pharmaceutical scientists and technologists up-to-date IDEAL INTRODUCTORY TEXT - Covers basic engineering principles, drug production, and development processes, so scientists can easily convert bulk pharmaceutical products into patient-ready dosage forms NEW INFORMATION - on quality principles that include quality by design; mathematical and statistical approaches to experimental design; computer aided design; and PAT (process analytical technology) keeps professionals at the forefront of their field COMPREHENSIVE COVERAGE - Step-by-step methods of drug production, knowledge of major unit operations, and key concepts of pharmaceutical engineering will help to improve communication among the varied professionals working in the pharmaceutical industry.
(source: Nielsen Book Data)9781420084764 20160612
Book
xviii, 190 p. : ill. (some col.)
  • Definition and classification of biologics.- Development and pre-clinical pharmacology of biologics: Infliximab -- from the idea to the product. Adalimumab. Etanercept. Efalizumab (Raptiva) -- antibody characteristics, mode of action and preclinical development. Monoclonal antibody targeted radiation cancer therapy. The production of biopharmaceuticals.- Disease-specific applications and clinical trials: Treating autoimmune bullous skin disorders with biologics. Biologics in psoriasis. Biologic agents in psoriatic arthritis. Biologic therapies for rheumatoid arthritis targeting TNFa and IL-1. Biologics in Crohn's Disease and ulcerative colitis. Multiple sclerosis: new immunobiologics. Biologics in cutaneous lymphoma. Biologics in targeted cancer therapy.- Safety and Perspectives: Safety aspects of biologics -- lessons learnt from monoclonal antibodies. New biological therapeutics in the genome age. Evidence-based medicine's perspective on biologics.
  • (source: Nielsen Book Data)9783540290179 20160528
This is the first book comprising all relevant aspects for the clinical application of biologicals. All biologicals currently approved for clinical use are described in a standardized way concentrating on practically relevant aspects such as contra-indications or monitoring needs. The "differential therapy" with biologicals namely in the fields of dermatology, rheumatology, gastroenterology, and neurology is described in detail and summarized in treatment algorithms. Shorter sections on the biotechnology behind the biologicals as well as safety, regulatory, and pharmaco-economic aspects complement the more clinically-oriented central chapters.
(source: Nielsen Book Data)9783540290179 20160528
Book
xviii, 190 p. : ill. (some col.)
Book
x, 359 p. : ill. ; 24 cm.
SAL3 (off-campus storage)

Articles+

Journal articles, e-books, & other e-resources
Articles+ results include